Search

Background Immune checkpoint inhibitors (ICI) can achieve durable responses in a subset of patients with locally advanced or metastatic urothelial carcinoma (aUC). The use of tumor genomic profiling in clinical practice may help suggest biomarkers to identify patients most likely to benefit from ICI.Methods We undertook a retrospective analysis of patients treated with an ICI for aUC at a large academic medical center. Patient clinical and histopathological variables were collected. Responses to treatment were assessed for all patients with at least one post-baseline scan or clear evidence of clinical progression following treatment start. Genomic profiling information was also collected for patients when available. Associations between patient clinical/genomic characteristics and objective response were assessed by logistic regression; associations between the characteristics and progression-free survival (PFS) and overall survival (OS) were examined by Cox regression. Multivariable analyses were performed to identify independent prognostic factors.Results We identified 119 aUC patients treated with an ICI from December 2014 to January 2020. Genomic profiling was available for 78 patients. Overall response rate to ICI was 29%, and median OS (mOS) was 13.4 months. Favorable performance status at the start of therapy was associated with improved OS (HR 0.46, p=0.025) after accounting for other covariates. Similarly, the presence of a TERT promoter mutation was an independent predictor of improved PFS (HR 0.38, p=0.012) and OS (HR 0.32, p=0.037) among patients who had genomic profiling available. Patients with both a favorable performance status and a TERT promoter mutation had a particularly good prognosis with mOS of 21.1 months as compared with 7.5 months in all other patients (p=0.03).Conclusions The presence of a TERT promoter mutation was an independent predictor of improved OS in a cohort of aUC patients treated with an ICI who had genomic data available. Most of the clinical and laboratory variables previously shown to be prognostic in aUC patients treated with chemotherapy did not have prognostic value among patients treated with an ICI. Genomic profiling may provide important prognostic information and affect clinical decision making in this patient population. Validation of these findings in prospective patient cohorts is needed.

In this study, the production of titanium powder via hydrogen reduction of titanium tetrachloride by inductively coupled radio frequency plasma was investigated. While titanium tetrachloride is hard to be reduced by hydrogen thermodynamically, dissociated hydrogen radical which formed from hydrogen gas passing through the plasma can react with titanium tetrachloride to form hydrochloric acid and subsequently produce titanium. The frequency of generator used in this experiment was 13.56 MHz and input power was varied. The characteristics of the powder such as powder size, size distribution, and phases were analyzed with x-ray diffractometer, field emission scanning electron microscope, energy dispersive x-ray spectrometer and transmission electron microscope. The deposited height of titanium powders, after 4 minutes reaction, were 4.004 μm and loosely attached that could be easily collected. The morphology of powders was found to be more spherical with the increase in applied input power. Most of the powders were composed of titanium and oxygen. The average diameter of powders was approximately 200 nm.

Fetal rhabdomyomas are a rare neoplasm composed of immature striated muscle cells that resemble rhabdomesenchymal cells during weeks 6-10 of embryogenesis. This tumor, though well-described in many anatomic locations, is most commonly found in the head and neck region. We report a case that highlights the difficulty in diagnosing a fetal rhabdomyoma in the lacrimal gland of a 56 year old woman. This case report gives an overview of this rare neoplasm, detailing the presentation, diagnosis, and treatment.

The conduction band edge (ECB) energy levels of a mesoporous TiO2 film were investigated in aprotic dimethylformamide (DMF) and aqueous media to explore the influence of various proton additives and electron donors. Spectroelectrolysis (SE) technique was employed to measure the ECB in non‐aqueous solvents, revealing a significantly negative ECB in dry non‐aqueous solvents compared to values obtained in aqueous solvents. In non‐aqueous DMF, the ECB of TiO2 was found to be highly dependent on the proton‐donating additive due to the establishment of a proton adsorption–desorption equilibrium, reaching –(1.42–1.94) V versus SCE. The introduction of a well‐known electron donor, 1,3‐dimethyl‐2‐phenyl‐1,3‐dihydrobenzimidazole (BIH) led to a slight positive shift in the TiO2ECB, indicating that the electron donor contributes to the to the CB energetics of the mesoporous TiO2 films. Under aqueous conditions and in the presence of various electron donors (TEA, TEOA, ascorbic acid, EDTA•2Na, and sodium ascorbate), the proton‐donating/accepting capacity of the additive significantly influenced the pH of the aqueous solvent, causing changes in the TiO2ECB across the electrolyte solution. This study emphasizes the crucial role of proton additives and electron donors in influencing the CB energetics of mesoporous TiO2 electrodes and aims to determine the extent to which the ECB of TiO2 can shift as a result of the adsorption and intercalation of protons on its surface. The findings obtained herein contribute to the understanding of the energy efficiency of TiO2‐mediated photocatalytic systems in various solvent environments. [ABSTRACT FROM AUTHOR]